BEIJING, Dec. 29, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, recently announced the commercial launch of i

DALIAN, China, Dec. 17, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the live attenuated vari

BEIJING, Dec. 16, 2025 – Results from a Phase III clinical study evaluating both humoral and cellular immune responses induced by SINOVAC's quadrivalent influenza vaccine (Sinovac-QIV) have been p

SÃO PAULO, Nov. 25, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has entered into a long-term strategic cooper

BEIJING, Nov. 7, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, today announced that its live attenuated varicel

BEIJING, October 30, 2025 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the National Medical

BEIJING, Oct. 25, 2025 – A head-to-head Phase III clinical trial published in Vaccines showed that SINOVAC's varicella vaccine had a more favorable safety profile than a WHO-prequalified comparato

BEIJING, Oct. 10, 2025 – SINOVAC's quadrivalent influenza vaccine, produced by its subsidiary Beijing Sinovac Biological Products Co., Ltd., has received approval from the National Medical Product

BEIJING, September 1, 2025 – SINOVAC's 23-valent pneumococcal polysaccharide vaccine (PPSV23) induces a significant immune response and maintains a favorable safety profile in individuals aged two

BEIJING, Aug. 29, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, hosted the 2025 Supply Chain Eco-Conference at

BEIJING, August 14, 2025 – the immunogenicity and safety profiles of SINOVAC's quadrivalent influenza vaccine (IIV4) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), particularly when a

BEIJING, July 25, 2025 – Bilive®, the only hepatitis A and B combined vaccine approved in China, received a drug re-registration approval notice on July 21, 2025. Manufactured by Beijing Sinovac Biolo

BEIJING, June 9, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced that its live attenuated varicella vac

BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 1

BEIJING, May 13, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced the signing of a strategic vaccine coo

BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common sha

BEIJING--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a

BEIJING, Apr. 21, 2025 — SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") has dispatched the inaugural shipment of its 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) to Aze

BEIJING – Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company’s board of directors (the “Board”

BEIJING – Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (th